Indoco Remedies Announces 79th AGM on Sep 17, 2026; Proposes Final Dividend of ₹0.20
Indoco Remedies will hold its 79th AGM on September 17, 2026. The company proposes a final dividend of ₹0.20 per share for FY26. Key events include e-voting from September 13-16, 2026. Ms. Aditi Panandikar's reappointment as MD and Dr. Vasudha Kamat's continuation as Independent Director are on the agenda. The company also seeks to increase borrowing limits to ₹1,500 Crores.
The AGM includes important corporate actions such as dividend approval, re-appointment of a key management personnel (Managing Director), and significant increase in borrowing limits, which can impact the company's financial strategy and governance.
The announcement is a routine corporate event (AGM) and includes standard proposals like dividend declaration, director re-appointments, and borrowing limit increases. There are no immediate financial results or significant new business developments mentioned that would strongly influence sentiment.
Indoco Remedies Limited has announced the date for its 79th Annual General Meeting (AGM), which will be held on Thursday, September 17, 2026, at 10:30 a.m. IST, via video conference and other audio-visual means. The company will also present the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026. A final dividend of ₹0.20 per equity share for the financial year 2025-26 will be proposed for approval.
Key dates for shareholders include Thursday, September 10, 2026, as the final dividend record date and the cut-off date for e-voting. Remote e-voting will commence on Sunday, September 13, 2026, at 09:00 a.m. IST, and conclude on Wednesday, September 16, 2026, at 05:00 p.m. IST. The book closure for the purpose of dividend and AGM will be from Friday, September 11, 2026, to Thursday, September 17, 2026, inclusive.
During the AGM, shareholders will vote on the re-appointment of Ms. Aditi Panandikar as Managing Director for a term of five years from February 15, 2027, to February 14, 2032. The company also seeks approval for the continuation of Dr. (Ms.) Vasudha V Kamat as a Non-Executive Independent Director beyond the age of 75, until September 23, 2030. Furthermore, the company plans to seek shareholder approval to increase its borrowing limits up to ₹1,500 Crores and to approve the creation of a mortgage or charge on the company's assets.
What to do with a filing like this
Indoco Remedies Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indoco Remedies Limited. Read the original for the full detail.